SWOG Cancer Research Network
SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.
Founded 1956 (Southwest Oncology Group). NCI National Clinical Trials Network member with >12,000 members at >1,300 sites. Landmark trials include S1826 (nivolumab-AVD in advanced Hodgkin lymphoma, FDA approval March 2026), S1418/BR006 (adjuvant pembrolizumab in TNBC), and the de-escalation trial SCARLET (S2212) in stage II-III TNBC. Statistical centre at Fred Hutchinson Cancer Center.
- NCTN cooperative group
- S1826 Hodgkin lymphoma
- SCARLET S2212 (TNBC de-escalation)
- Cancer control and survivorship
Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.
Anne Chiang is a thoracic oncologist overseeing SWOG's breast and lung trial portfolios.
Charles Blanke is a GI oncologist who chaired SWOG for a decade and led early imatinib trials in GIST.
Breast oncologist who co-leads SWOG and studies adherence, toxicity, and how care is actually delivered.
Hagen Kennecke is a GI oncologist who leads SWOG's gastrointestinal and melanoma committees.
Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.
Mariana Chavez-MacGregor is a breast oncologist who studies how care is delivered and leads SWOG's international work.
Michael LeBlanc is the statistician behind SWOG's trials, based at Fred Hutch's statistical centre.
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Primo Lara is a GU and lung oncologist who co-chairs SWOG and directs UC Davis's cancer centre.
Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.
Virginia Sun is a nurse scientist who leads SWOG's supportive care and survivorship research.
Pages like this
not linked directly; found by shared links- InstitutionECOG-ACRIN Cancer Research Group
Shares Follow every trial participant for 30 years through registry linkage, A publicly held library of investigational drugs available for academic combination trials, A fixed share of trial-group funding for getting proven care to patients, Older and multimorbid patients are excluded and undertreated.
- PairingPD-1 blockade + AVD chemotherapy
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Hodgkin lymphoma, Nivolumab.
- ProductBrentuximab vedotin
Shares Alex F. Herrera, SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Hodgkin lymphoma.
- IdeaStop over-excluding people who could become pregnant; study pregnancy exposure
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly, Hodgkin lymphoma, Triple-negative breast cancer (TNBC).
- IdeaA trials fund reserved for older and multimorbid patients
Shares A fixed share of trial-group funding for getting proven care to patients, Older and multimorbid patients are excluded and undertreated, Trials do not represent the people who get cancer.
- TrialRxPONDER (SWOG S1007)
Shares Kathy S. Albain, Winship Cancer Institute of Emory University.
- PairingNeoadjuvant immunotherapy → response-adapted adjuvant
Shares SWOG S1801, Nivolumab, Melanoma.
- Key paperECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma
Shares SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Hodgkin lymphoma.